Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -88.11
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ARAV)
- Company Aravive, Inc.
- Price $0.04
- Changes Percentage (-13.39%)
- Change -$0.01
- Day Low $0.04
- Day High $0.05
- Year High $2.46
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.25
- High Stock Price Target $0.25
- Low Stock Price Target $0.25
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.76
- Trailing P/E Ratio -0.052763157894737
- Forward P/E Ratio -0.052763157894737
- P/E Growth -0.052763157894737
- Net Income $-80,921,000
Income Statement
Quarterly
Annual
Latest News of ARAV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tharavadu, Leeds: 'It'll make you profoundly happy' - restaurant review
Tharavadu in Leeds offers warm hospitality and delicious Keralan cuisine. The menu features detailed descriptions of each dish, showcasing the bold flavors and aromatics of South India. The restaurant...
By The Guardian | 2 weeks ago -
Family of five escape moving caravan during brazen Queensland car theft
In northwest Queensland, a family of five narrowly escaped a stolen caravan after a car thief took off with it. The parents and three kids aged 6-12 were inside when the caravan started moving. They m...
By The Guardian | 1 month ago -
Caravan of 3K migrants hope to cross southern border into the US...
Approximately 3,000 migrants are heading towards the US border to seek asylum before the election, fearing potential restrictions by a re-elected Trump administration. Migrants are utilizing an app to...
By New York Post | 2 months ago
